12:50 | Keynote Understanding and exploiting posttranslational modifications: inteins and Ubiquitin/SUMO H.D. Mootz, University of Münster/D |
13:30 | Chemical biology of Ub signal transduction and DUB inhibition H. Ovaa, Netherlands Cancer Institute, Amsterdam/NL |
13:50 | Species selective epigenetic therapy: smHDAC8 as a target to combat the Schistosoma mansoni M. Jung, University of Freiburg/D |
14:10 | Biochemical modulation of small GTPases by pathogenic bacteria A. Itzen, TU München/D |
14:30 | Coffee break |
14:50 | Keynote Protein semi-synthesis and drug discovery of post-translational modified nuclear receptors L. Brunsveld, TU Eindhoven/NL |
15:30 | Peptide microarrays for enzyme profiling M. Schutkowski, University of Halle-Wittenberg, Halle/D |
15:50 | Concerted binding to DNA and histone H3 tail drives the recognition of H3K36 methylated nucleosomes R. van Nuland, F.M.A. van Schaik, UMC Utrecht/NL; M. Simonis, S. van Heesch, E. Cuppen, Hubrecht Institute, Utrecht/NL; R. Boelens, Utrecht University/NL; H.Th.M Timmer, UMC Utrecht/NL; H. van Ingen, Utrecht University/NL |
16:10 | Proteomic analysis of changes in protein acetylation in inflammation T. van den Bosch, F.J. Dekker, University of Groningen/NL |
16:30 | Coffee break |
16:50 | Lectures of selected posters |
17:25 | Keynote Bedaquiline - TMC207, a new candidate for the treatment of drug resistant tuberculosis J. Guillemont, Janssen, Val De Reuil/F |
18:05 | Postersession & Get together |
09:00 | Keynote Interference with bacterial cell to cell communication - a novel strategy for anti-virulence anti-infectives R.W. Hartmann, Helmholtz-Institute for Pharmaceutical Research Saarland and Saarland University, Saarbrücken/D |
09:40 | Acyldepsipeptide antibiotics, a tool for elucidating structual dynamics and function of caseinolytic peptidase P H. Brötz-Oesterhelt, University of Düsseldorf/D |
10:00 | Chemical Exploration of the FK506-Binding Protein 51 F. Hausch, Max-Planck-Institut für Psychiatrie, Munich/D |
10:20 | 2-CLIPS peptides, a new class of biopharmaceuticals P. Timmerman, Pepscan Therapeutics B.V., Lelystad/NL |
10:40 | Coffee break |
11:00 | Keynote Covalent agonists facilitating crystallization of GPCRs P. Gmeiner, University of Erlangen-Nürnberg, Erlangen/D |
11:40 | Targeting tankyrases J. Waaler, A. Voronkov, Oslo University Hospital/N; D. Holshworth, StemNext LLC, San Diego, CA/USA; S. Krauss, Oslo University Hospital/N |
12:00 | Probes to image the catalytic activity of serine proteases K. Augustyns, University of Antwerp/B |
12:20 | Target validation and drug discovery in Alzheimer's Disease and inflammatory disorders - Glutaminylcyclases (QC) as new therapeutic targets H.-U. Demuth, Fraunhofer-Institute of Cell Therapy and Immunology (IZI), Halle/D |
12:40 | Lunch break |
13:40 | Keynote Function and fate of cellular carbohydrates V. Wittmann, University of Konstanz/D |
14:20 | Chemical probes for studying oxidative crosslinking reactions in the biosynthesis of glycopeptide antibiotics C. Brieke, K. Haslinger, M. J. Cryle, Max-Planck Institute for Medical Research, Heidelberg/D |
14:40 | C-type lectin receptors as targets for immune modulation: from glycan arrays to murine studies T. Johannssen, S. Zimmermann, J. Hütter, M. Eriksson, M. Maglinao, B. Lepenies, Max Planck Institute of Colloids and Interfaces, Potsdam/D |
15:00 | Keynote Semisynthetic glycoproteins: new tools for basic and medical research C. Unverzagt, University of Bayreuth/D |
15:40 | Closing |